<SEC-DOCUMENT>0001193125-14-415209.txt : 20141117
<SEC-HEADER>0001193125-14-415209.hdr.sgml : 20141117
<ACCEPTANCE-DATETIME>20141117163512
ACCESSION NUMBER:		0001193125-14-415209
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141114
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141117
DATE AS OF CHANGE:		20141117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330024450
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		141228279

	BUSINESS ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858 597-6006

	MAIL ADDRESS:	
		STREET 1:		10480 WATERIDGE CIRCLE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d822715d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of
earliest event reported) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;14, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-14888</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>33-0969592</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>19462</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: <U>(267)&nbsp;440-4200</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;1.02</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Termination of a Material Definitive Agreement</U>. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;9, 2013, Inovio
Pharmaceuticals, Inc. (the &#147;Company&#148;) enter into a Collaboration, Option and License Agreement with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc. (the &#147;Agreement&#148;). On November&nbsp;14, 2014, the parties partially terminated the
Agreement with respect to the development of INO-5150, the Company&#146;s DNA immunotherapy targeting prostate cancer, as well as the research collaboration in prostate cancer under the Agreement. All of Roche&#146;s rights to INO-5150, including
the right to license the product to other parties, will be returned to the Company. The Company plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Roche will continue to collaborate and co-develop the Company&#146;s DNA immunotherapy (INO-1800) against hepatitis B virus
under the existing license under the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued a press release on November&nbsp;17, 2014, and the Company
incorporates by reference the text of that press release into this Form 8-K current report. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><U>Item&nbsp;9.01</U>.</TD>
<TD ALIGN="left" VALIGN="top"><U>Financial Statements and Exhibits</U>. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:62.75pt; font-size:8pt; font-family:Times New Roman">Exhibit Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated November 17, 2014</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INOVIO PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Peter Kies,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November&nbsp;17, 2014 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d822715dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g822715ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CONTACTS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, <U>bhertel@inovio.com</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals to Independently Develop Prostate Cancer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immunotherapy; Will Maintain Collaboration and License Agreement </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with Roche for Inovio&#146;s Hepatitis B Immunotherapy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa. &#150; November&nbsp;17, 2014 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated
their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio&#146;s DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. All of Roche&#146;s rights to INO-5150, including
the right to license the product to other parties, will be returned to Inovio. Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio and Roche will continue to collaborate and co-develop Inovio&#146;s DNA immunotherapy (INO-1800) against hepatitis B virus under their existing license
agreement. The partnership is on track to move INO-1800 collaboratively into a phase I study in 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, Inovio&#146;s
president&nbsp;&amp; CEO, said, &#147;The Inovio/Roche partnership will continue to thrive focusing on the development of INO-1800 for the treatment of hepatitis B. In addition to recently demonstrating clinical efficacy and the ability to induce
potent antigen specific CD8+ T cell responses in our VGX-3100 phase II study, Inovio will be moving a broad portfolio of immuno-oncology products through development, including INO-3112 (head/neck and cervical cancers), INO-1400 (breast, lung and
pancreatic cancers) and INO-5150 (prostate cancer). We believe that these products along with pre-phase III VGX-3100 will further our growth and represent opportunities for additional value-adding partnerships.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INO-5150 for Prostate Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s
dual-antigen synthetic DNA immunotherapy (INO-5150) targets prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA). A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses
that were the highest generated by a PSA-targeting immunotherapy in animal studies and were similar to the immune responses generated by VGX-3100, Inovio&#146;s phase II-completed HPV immunotherapy that generated best-in-class T-cell responses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio&#146;s SynCon&reg; DNA vaccine for prostate cancer was designed with PSA and PSMA synthetic consensus immunogens based on human and macaque sequences,
resulting in amino acid sequences that differ slightly from the native human protein. In humans, this novel approach is utilized to help the body&#146;s immune system recognize cancerous cells created in the body as &#145;foreign&#146;, overcoming
the body&#146;s self-tolerance of these cells and mounting an immune response to clear them. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INO-1800 for Hepatitis B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio has reported preclinical data showing its hepatitis B vaccine (INO-1800) generated strong T-cell and antibody responses that led to the elimination of
targeted liver cells in mice. These results indicate this DNA immunotherapy&#146;s potential to treat hepatitis B infection and prevent further development of the infection into liver cancer in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a preclinical study, researchers found the vaccine-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause
clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is revolutionizing the fight against
cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer
immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include&nbsp;Roche, MedImmune, the&nbsp;University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial
Network,&nbsp;National Cancer Institute, U.S. Military HIV Research Program,&nbsp;US Dept. of Homeland Security, and&nbsp;University of Manitoba.&nbsp;For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital
resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not
limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results
desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the
results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immune therapy and vaccine products, our ability
to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its
collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand
claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company&#146;s technology by potential
corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013, our Form 10-Q for
the quarter ended September&nbsp;30, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio&#146;s pipeline will be </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking
information provided herein will be proven accurate. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g822715ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g822715ex99_1pg001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!=`0D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]"?\`@KA^
MV#XQ^%WC31O`WA35+SP]#<:>-2O[VT8QW-QO=T2-9!RJC82=N"2P&<#GE?\`
M@E5^V?XX\2_'2+P)XEUO4?$NE:U:SRVTE_*9Y[&6)#)D2-\Q1E5@5).#@C'.
M?JK]LW]A#PW^V/8:?-?7MUH>O:2K1VNI6T:R'RV.3%(AP'7/(Y!!)P>2#C_L
M8_\`!.7PW^R)K5UK@U2Z\2>)+J$VRWD\*P1VL1(++'&"<%B!EB2<#`P,Y`/H
MNBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_
M(O\`:_\`V]?B3XZ^//B"+2_%.N>&=%T34)K&PL=-NGM0JQ.R;Y"A!=V*DG<2
M!G``Q7VO_P`$L_VGO$/[2'P4U*/Q1,;_`%CPS>K9M?E0K7D3(&0OC@N.02.N
M`>I-87[2O_!(SPQ\=?B?>>*-)\17WA2YU>7S]0MH[1;F":4_>D0%E*,W4C)!
M))P,U[Q^S+^S5X>_96^&,/AGP\L\L9D-S=W=P09[V=@`TCX``X```X``'N0#
MT*BBB@`HHHH`****`"BBB@#/\0>+=*\)0QR:KJ>GZ9',Q6-KNY2$.1S@%B,F
MF>'_`!MHOBUY5TK5]+U-H`#(+2ZCF,8/0G:3C.#U]*^+?^"Y$2R_"SP'N56Q
MJ\_49_Y85QW_``0QA2+Q=\1=J*N;.QZ#'\<U`'Z+5DZ_X^T+PI=I!JFM:3IL
M\B[UCNKR.%V7.,@,02,@\^U:U?F#_P`%M8$E_:3\-%D5B/#J=1G_`)>)J`/T
MQT'Q+IWBFS-SIFH66HVZL4,MK.LR!AU&5)&>1Q[UY]\2?VS_`(5_"+57L/$'
MCG0+&^C.)+99S/-&?1DC#%3]0*_*SP!^UQXH\`?LV#X7^#A=Z;/K>KSW5]>6
M>?M5TDJ11I;0[?F7)0[B/F.0!WST_@[_`()3_&OQ?HZ7Q\.V&DK.-ZQ:EJ*0
MW!S_`'D&XJ?9L&@#])_A_P#MM_";XHZI'8Z)X]\/W5Y*<1P23FWDD/HJR!23
M["O4Z_#KX\_LL>.OV;;^W@\9>'YM.BNV*VUVCK/:W#`9(6121N`YVG!]J^RO
M^"1?[9NJ^)]8E^&'BB_FU`I;-<Z#=7#EY56,?O+9F/+`+\RYY`5ATQ@`^^Z*
M**`"BJVLZS:>'=)N;^_N8+.RLXVFGGF<)'$BC)9B>``*^1/VDOVC_'_Q.BDL
M?#&M/\)O!\XVIK#V`N_%&MI_>M+1_DM(C_#+/F0C!$:\$]%##^T=W)1BMV]O
MPNV_))LPK5_9K1.3[+^K+U;2/I_XD_&;PC\&],^V^+?$^@>&K4@L)-3OXK4,
M!Z;V&?PKQ;4/^"NW[->F7A@E^+_A1I`<$Q/+,G_?2(5_6OC%/^"<.D?$;59-
M6_X5OXF\?ZK<'=)K?C?7;F]N;@G^(J&15^@&!69\0O\`@D_=26#Y^#_AJ!`N
M=VG23PR+]")*]:C#)HZ5IU)><8Q2_%M_D>95GF\M:4*<?)N3?X)+\S]'?A3^
MV[\(/CA<+!X3^)/@W6[F0X6W@U2(3L?01L0Y_*O4J_G/^/O_``3_`-2\`WDD
MFF6>H:=<PG<+*_\`F.1_SSEP#GTW?G6_^QU_P5T^,O[%7B"#3+O4[WQAX5M)
M!%=>'M=F>1X%!P1!,V9(6'.!RGJM>U3X4P^.I.ME%?G:WC)6E_7RMYGCU.)Z
M^"JJEFM'D3VE%WC_`%^/D?T(UF>(?&NC>$FB75=7TS3#."8A=W20F3&,XW$9
MQD=/6N`_9!_;`\&?ML?!ZT\8>#+UI;=SY%[93X6[TNX`!:&9>S#.01PP(()%
M<%_P5$_9Q7X^?LS7UW:6JW&N^$"VK6.%R\B*O[^(?[T>3CNR+7Q=:C4HU'2J
MJTEHT^A]=1K0JP52F[Q>J:/>M`\>:'XLN7ATK6=)U*:)=[I:W<<S(N<9(4D@
M9[UJU^*?[#/QX7]FW]I/P]X@9Q#I-S)_9^J8X#6LQ"LQ]=AVO_P"OVKCD6:-
M71@RL,@@Y!'K69H+3+JZBLK:2::1(885+R2.P544#)))X``[T^OE+_@KG^T#
M_P`*I_9S_P"$9LI_+U?QS(;+"GYH[1<-.WX@K'_VT/I0!]$K\9/"#$`>*_#9
M)Z8U.#G_`,>KI`0P!'(-?CM_P37_`&;HOV@/VG=*6[LXY="\,8U?4=R`H^QA
MY41_WI-O'=5:OV)H`Q=9^)/AWPYJ#VFH:_HMA=(`6AN+Z**101D$JS`\BM'2
M-:L_$&GQW=A=VU]:RYV36\JRQO@X.&4D'D$5^27_``5IMXY/VXO$99$8_8K#
MDJ#_`,NZ5]Y_\$M$$?[#?@L*`H`N^`,?\O4M`'T'117A_P"VY^VUHW['O@B*
M5XH]5\4:JK#2],W[=^.#-*1RL2G\6/`[D`'LFN^(+#POIDE[J=]9Z=9PC,D]
MS,L,2?5F(`KR76O^"AOP4\/WK6]Q\1?#[2H<'R&>X4'_`'HU8?K7Y1_$[XQ_
M$+]KSX@1?VQ>:MXGU2\D*V>EVD;/#%G^&&!<@`>N">Y->D^&/^"4OQM\2:6E
MT?#>GZ8LB[EBOM3BCE_%5W8^AH`_3OX;?M3?#GXOW*P>&_&GA[5KEN%MXKQ5
MG;Z1MAC^5=]7XF?&G]BWXG?L\VW]H>)O"M[:V$)!_M*S=;JVB/8F2,G9]6Q7
ML_[$W_!4CQ%\&=7LM`\=WMWXC\'RLL0NYF,M[I0Z!@YYEC'=3D@?=/8@'ZF4
M56T76;3Q%I%KJ%A<0WEE>Q+/;SQ,&CFC8`JRD=000:LT`?#G_!<7_DEG@3_L
M+S_^B*X__@AK_P`C=\1/^O.Q_P#0YJ[#_@N+_P`DL\"?]A>?_P!$5Q__``0U
M_P"1N^(G_7G8_P#H<U`'Z)U^8?\`P6R_Y.2\-?\`8NI_Z435^GE?F'_P6R_Y
M.2\-?]BZG_I1-0!K_P#!%OX$67BWQ[XB\=:C;QW!\-+'9::'7(CN)06>0?[2
MH``>WF&OTEKX\_X(IV*0_LPZY.%P]QXBF#'UVP0`5]AT`>6?MK_"^S^+O[+?
MC72;N%)'CTR:^M69<F&>%#+&R^ARN/H2.]?DQ^QEXLD\&_M6?#S48G*;=<MH
M7(.,I*WE./Q5R*_9GXMC/PI\3_\`8)NO_1+U^)7[.W_)=_`O_8>T_P#]*(Z`
M/W6KYJ_X*>_\%#;+_@GK\$[368M.M]<\5>(+DV6BZ;-*8XG95W232D?-Y<8*
MY`Y)=1D9R/I6OPT_X.(OBM<>-?VX['P]YC&P\(:!!%%'GY1+.S2R-]2/+'_`
M17T?"F5T\?F,*-97BKM^:73[['@<39E/`X"5:EI)V2]7_P`"YZO^QA_P6V^(
M?[4WQ]T'X<^.O#OA2XM_%E\MOIMWIUO+"VGW."T9DC=W65`1WP5.&YQ7Z<^!
M_@%HWAB[;4+R(:IK$QWRW5S\[;CUQGI7XF?\$*_@]/\`$3]M"UUJ*,,/"L'G
MJY&?+>3*;OKM#C_@5?O<.E=7&N'PF'S'V&$ARJ,5=+:[U_*QS<(8C%5\![;%
M2YFV[/K9:?G<;'&L2A4554=`!@4[K117R1]0<7\7O@)X:^-/A^:QUG3K>4R*
M0LH0!T/J#7XI_P#!7']A.Y_9V\0#6X(B]H'"&=5XFB8X4M[J<#/H?:OW@KXZ
M_P""XWA"PU?]@CQ9JETD8GTR)#$Y'.YI$4#\R*]KAW&5,-F5&I3>\DGYINS1
MY&?X2GB,OJPJ+:+:\FE=,_*S_@CW^V!>_LF_ME^'TENWC\*^-[B+0M;@9L18
ME;;!<$=`T4K*<]=K..]?T+R1K+&RLH96&"",@CTK^4C2;F6SU6UFA)6:*9'C
M(ZA@P(_6OZHO`6JR:[X(TB]E.9;JSBE?_>*`G]:^O\2,'3AB*6(BM9II_P#;
MMK?G;Y'RGA]BYSP]6A+:+37SO_D?CC^W;^SV?V;_`-I+7M"AA,>C7K_VCI1Q
M\IMI22$'^XVY/^`#UK]&_P#@F'^T%_PO;]E_38+R?SM;\)D:/?;CEW5%'DR'
M_>CVC/=D:N/_`."O_P"SS_PLWX"0^,+"#?JW@AS-*5'S264F!*/?80K^P5_6
MODS_`()5_M`_\*6_:<M-*O)_+T7QJJZ7.&.%2XSFW?\`[[)3/I+7YL?H1^ME
M?C=_P46_:"_X:#_:?UN\MI_-T30"=(TT@Y1HXF.^0?[\A<Y]-M?I%_P4*_:"
M_P"&=_V8M<U&VG$6M:PO]E:7@_,)I007'^X@=\^JCUK\OOV+?@!)^TE^T7X?
M\-O&[Z8LOVW57'\-I$0S@G_;.U![O0!^B_\`P2K_`&>/^%)_LTVNK7L'E:YX
MU9=4N-RX>.`C%O&?^`'?]9#7TS3+>WCM+=(HD6.*)0B(HPJ@#``'I3Z`/R,_
MX*S?\GP>(_\`KRL?_2=*^\?^"6__`"8[X+^EW_Z52U\'?\%9O^3X/$?_`%Y6
M/_I.E?>/_!+?_DQWP7]+O_TJEH`][U74X-%TRYO+J18;:TB:::1NB(H)8GZ`
M&OQ#_:/^-6J_M1?'G5_$DPFGDU:Z%OIEJ.3#;AML$*CUP1GU9F/>OUM_;FUV
M;PW^R!\1;NW9EF71+B,$=1O78?T8U^6'[`?ANW\4_MD_#RSN55H$U07)5NC&
M*-Y5'_?2"@#],/V%OV+]'_90^&=L9+:"Y\8ZI"LFKZ@5#.K$9\B,_P`,:=,#
M[Q!8]L>ZT44`1W=I%?VLD$\4<\$RE)(Y%#(ZD8((/!!':ORK_P""HG[%EE^S
M?XZL_$WAFV^S>$_$\KH;51\FFW8&XQKZ1NN64=MK#H!7ZL5\Z?\`!5?PU;^(
M/V)?%$LZJ9-*FM+V`G^%Q<(F1_P%V'XT`>3?\$8/VB;CQ3X,UGX=:G<--+X<
M47^E%SDBU=L21#V20@CVDQT%?<E?DA_P23UF72_VV=#AC9@FHZ?>V\H'\2B$
MR#/_``*-:_6^@#X<_P""XO\`R2SP)_V%Y_\`T17'_P#!#7_D;OB)_P!>=C_Z
M'-78?\%Q?^26>!/^PO/_`.B*X_\`X(:_\C=\1/\`KSL?_0YJ`/T3K\P_^"V7
M_)R7AK_L74_]*)J_3ROS#_X+9?\`)R7AK_L74_\`2B:@#Z"_X(N?\FG:E_V,
M=U_Z)@KZZKY%_P""+G_)IVI?]C'=?^B8*^NJ`.?^+7_)*O$W_8)NO_1+U^)/
M[.W_`"7?P+_V'M/_`/2B.OVV^+7_`"2KQ-_V";K_`-$O7XD_L[?\EW\"_P#8
M>T__`-*(Z`/W6K\#/^"[OAF;2_V]=4U)E;R=5L8=K'INCRA'Y;?SK]\Z_-3_
M`(+G_L<R_$O3;;Q/8Q`7$8RDN.$D`QAC_=8<?D>U?1<*YI#`9E"M5^%WB_)/
MK\G;Y'@<39;/'9?.C3^)6:\VNGS5SP[_`(-K?&NG:;^T;XZT"Z>-+_5=$BO+
M(,>9/)E*R*/?;*I^@-?LY7\O/P3^+_BK]DCX[Z+XNT,OIWB3PM>"58I@0LHP
M5DAD`ZQR(64XZALCM7]"/[#'_!0;P%^WA\.H=4\-7\5IK]M$IU;0+B0"]TR3
MO\O\<>?NR*-I&.AR!]#QYD]18G^TJ2YJ<TKM:V:5ON:M9GA<$YK3>'_L^H[3
M@W9/JKW^].]T>ZT445^>'W@5^:__``<E_'+4/"7P"\&^!+.)EM/%^I27>H7'
M;9:A62'_`($\@;_ME7Z,>*?%>E^!_#]UJVM:C8Z3I=C&9;F[O)U@@@0=69V(
M`'U-?$7[<_P:?_@H9H6GWV@:8;O0(038?VC$T3ZP/^?B&-@'2''W7;!?)(&W
M!;ULEQ,<)BZ>-JPYH0>OKTMYIZV\CR\WPTL5A9X2E/EE-?AU^3VOYGXV?LM?
M"Z?XQ?'_`,+Z%#$TD<]_%+<8&=L2.&;/UQC\:_IM\%Z<=(\(Z;;-U@MD0_@H
MKX+_`.">W_!+.;X+>/X]?U?1[+28K4[DB0;I)6'3).3@5^@X`4`#@"O0XIXA
M6:XF,Z<7&$59)[Z[O^NQP<-9$\LP\H3:<Y.[MMY+^NY6UK1[;Q#H]WI]["EQ
M9WT+V\\3C*RQNI5E/L02*_$/]I3X,WW[-/Q]U[PNSS1MH]WYNGW'1I(&.^"4
M'UVE?^!*?2OW%KX:_P""T/[/'_"0^!]'^(^GP9NM!8:=JA4<M:R-^[<_[DAQ
M])?:OF3Z,^5?VU_VS;W]K4>"TD26W@\/Z0B7<;<+-J#@">4#^[\JA?Q]:^Q_
M^"./[//_``@'P7O?'-_!MU/QD^VT+#YH[*(D+CTWON;W`2OSU_9\^#E[\?\`
MXS^'O"%B'#ZS=K'-(HS]G@'S2R?\!0,?KBOW$\,>'+/P=X<L-)TZ!;:PTRWC
MM;:)>D<:*%4?@`*`+U%%%`'Y&?\`!6;_`)/@\1_]>5C_`.DZ5]X_\$M_^3'?
M!?TN_P#TJEKX._X*S?\`)\'B/_KRL?\`TG2OO'_@EO\`\F.^"_I=_P#I5+0!
MZ?\`M%_#Y_BO\!_&'AR(;I]9TFXMH1ZR&,[/_'L5^,7[/OQ);X'_`!Y\*^)K
MB.11X?U2*:ZCQAA&&VRKCUV%Q7[H5^6?_!5#]C*[^#?Q+N_'FAV;OX1\37!F
MNO*7Y=+O'.75L=$D;+*>@8LOID`_432=5MM=TNVOK.:.YM+R)9X)HSE)48!E
M8'N""#5BORY_8+_X*>S_`+/6B6_@_P`:P7FJ^$X#ML;RW'F76E*3]PJ?]9%G
MH`=R]LC`'W9X7_;O^#WB[35NK3XA^&(T89*75V+65/8I)M8'\*`/6J^/_P#@
MLI\9+7PA^SO:>$8YE.J>+;V,F('YEMH&$CN1V!<1J/7)]*Z?XZ_\%6OA7\*-
M'G&BZJOC360I$-II>6AW=O,G(V*OTW'VK\T_B[\6O&'[7WQJ.JZA'-JFOZU*
MEI8:?:(66%<_N[>%>N!D\GDDEB>30![U_P`$:/AS/XG_`&H+WQ!L;['X8TF4
ML^./-G(C1<^I7S3_`,!K]2Z\2_8*_92C_9.^!T&EW7E2^(]6<7VLS1G*^<1A
M8E/=8U^4'N=Q[U[;0!\Z?\%%?V/O$'[8'@WPWIOA_4M(TV;1KZ2ZF;4#(%=6
MCV@+L5N<^M87_!.?]A7Q/^Q[KGBJZ\0:MH>I)KL%O%"-/,I,9C:0G=O5>N\8
MQ[UW'C?]IWXB^&/&.IZ=IWP`\=:_86-R\-OJ=MK.DQ0WZ`\2HLERKJI[!E!]
M167_`,-<_%+_`*-J^(G_`(/=%_\`DNNZ.7UFKIQ_\#A_\D<;QU).S4O_``&7
M^1]"5\??\%"?^">?BW]KCXLZ3K^@:SX?TZUT_2EL7COS,)&<2R/D;$(QAQ7>
M_P##7/Q2_P"C:OB)_P"#W1?_`)+H_P"&N?BE_P!&U?$3_P`'NB__`"73_LVM
MWC_X'#_Y(7]H4NTO_`)?Y&E_P3__`&8=:_9-^"=WX9UZ_P!,U&]N-6FOUEL2
MYB"/'$H!WJ#G*'MW%>Y5\]_\-<_%+_HVKXB?^#W1?_DNC_AKGXI?]&U?$3_P
M>Z+_`/)=']FUN\?_``.'_P`D']H4NTO_``"7^1[AXWT.7Q-X+U?38'2.;4+*
M:VC9\[59XV4$XYQDU^>GPK_X(X?$/P+\2?#>LW7B7P?+;Z-J=K>S)$UQO=(I
M5=@N8P,D*<9KZ;_X:Y^*7_1M7Q$_\'NB_P#R71_PUS\4O^C:OB)_X/=%_P#D
MNC^S:W>/_@</_D@_M"EVE_X!+_(^A*Q?B#X`TWXE^%KK2-5MTN+2Z0JP89Q[
MBO%?^&N?BE_T;5\1/_![HO\`\ET?\-<_%+_HVKXB?^#W1?\`Y+H_LVMWC_X'
M#_Y(/[0I=I?^`2_R/AS]N[_@DM<Z?>SWUIITNIZ;DF&ZM1BYMA_=)[CV.17P
MZ?V7?'/P@\90:MX2U^?3-7T^3=;7,=Q)IU[;GV=>/U`/I7[A3_M9?$^YB*2?
MLS_$)T;@JVN:(0?_`";KSKQ^^I_$J1GU/]DKQTTK=7BUO1$8_P#DU7O99FF;
M8&'LJ4XN'\LI0:_]*T^31XF8Y;E>-E[2K"2G_,HS3_\`2=?G<^*?@Y_P4>_;
M5\%V4%B8?#?C>"(!$DU>.T:4C_:EBFB+?5@37KMK^W/^V!X]A6._U#X'_#*W
M<?-=.&U"Z0>JPK+*"?8BNYN/V>1->"5?V7?BI$!_"OB31`#_`.3-=3X.\&S^
M";A9;;]DWXA3R(<AKC7]$DQ_Y-5=;'U:CYEAJ"?=./Y<]OP)HX*G3T>(K-=F
MI?GR7_$X_P"$'P(U;XQ^+K+6/%.N^*OCAXDM)1-;WWB.,6OAW2),Y\RVTY/W
M18'D/(&([`&ONCX9_#I_"%F;C4+EM0U:X&9[A_7T7T%>.:3^T]\1M!M%@LOV
M8?'UK"@P$CUK1%`_*ZJU_P`-<_%+_HVKXB?^#W1?_DNO&Q-#%XB7-5E%VV7/
M!)>B327R1ZV'KX6C'EIQDK_W9MOU;5W\V?0E%?/?_#7/Q2_Z-J^(G_@]T7_Y
M+H_X:Y^*7_1M7Q$_\'NB_P#R77/_`&;6[Q_\#A_\D;_VA2[2_P#`)?Y'T)6+
M\1?`>G_%'P'K'AS58A-IVM6DEG<+CG:ZD9'N,Y![$"O%?^&N?BE_T;5\1/\`
MP>Z+_P#)='_#7/Q2_P"C:OB)_P"#W1?_`)+H_LVMWC_X'#_Y(/[0I=I?^`2_
MR/,/^"6?[%NH?`SQEXX\1>);8IJ=C>R^'],9UQOAC8&2X7/\,AV`'T5O6OM.
MOGO_`(:Y^*7_`$;5\1/_``>Z+_\`)='_``US\4O^C:OB)_X/=%_^2Z/[-K=X
M_P#@</\`Y(/[0I=I?^`2_P`CZ$HKY[_X:Y^*7_1M7Q$_\'NB_P#R71_PUS\4
MO^C:OB)_X/=%_P#DNC^S:W>/_@</_D@_M"EVE_X!+_(\A_;:_P""8GC3]IC]
MHG5?%^C:[X9L=/O[>VA2&\:<3*8XE0D[4(P2..:^D_V-_@CJ?[.G[.N@>#]7
MNK*]U#2?.\V:T+&%]\SR#;N`/1@.1UKBO^&N?BE_T;5\1/\`P>Z+_P#)='_#
M7/Q2_P"C:OB)_P"#W1?_`)+H_LVMWC_X'#_Y(/[0I=I?^`2_R/H2J?B#P_8^
M*]$NM-U.TM[_`$^^C,-Q;SQB2.9",%64\$5X/_PUS\4O^C:OB)_X/=%_^2Z/
M^&N?BE_T;5\1/_![HO\`\ET?V;6[Q_\``X?_`"0?VA2[2_\``)?Y'AW[1O\`
MP1;MM7U&XU/X9ZU#I8E)?^Q]4+/`A](IAEE'H&#8]:^;]<_X)<?'#1KPQ?\`
M"&QWP!XEM=2MI$;WY<'\Q7Z`_P##7/Q2_P"C:OB)_P"#W1?_`)+H_P"&N?BE
M_P!&U?$3_P`'NB__`"71_9M;O'_P.'_R0?VA2[2_\`E_D?$_PV_X(^?%OQC?
M1C64T/PI9$Y>6ZNQ<R@>T<603]6%?=/[)/[`/@K]DN'[;8)+K?B>6,QS:Q>J
MOFJ#U6%1Q$I[XR3W8UG?\-<_%+_HVKXB?^#W1?\`Y+H_X:Y^*7_1M7Q$_P#!
M[HO_`,ET?V;6[Q_\#A_\D']H4NTO_`)?Y'T)17STW[77Q2521^S3\120,@#7
M=$Y_\FZ[[_A<?BS_`*)?XD_\&%C_`/'JSJ8*K#>WRE%_DRX8RG+:_P#X#)?F
MCS3_`(*"?M3ZU^SEXB^%.FZ;XN\$^`[#QSKEYIVI:_XGLVNK2QC@TZYND`43
MP#=))"B9+_Q<`FNX_8B^/&M_M(_L\:;XJU_3[.SOKB\O;2.XLH9H;+6((+J6
M&'4+:.;]ZD%Q&BS(KY(60<L,,;_QE^`4'Q6^,GPK\43W_P!G'PZU6^U%;-K9
M9DU`W&G7%GM+$C9M\_>"`<E<<9R/2ZY#J/#OVX/VKS^R19?#/5+F:PM=#\3>
M-K;P_K5S<P2S&VM);.\E+QK'\WF>9!$`<,,,W'<<]\.?^"@>@?'+]M/0/A]X
M(U;3];\/W/A#5-=U*8V5S!<V]S!=V$,"J950%&2XFR`"<JO([^E?M!?`E/C5
MKWPVO6U633#X"\70>)E18!+]N,=I=V_D$EAL!%R6W#/W,8YX77O@2NL_M8^&
M?B2=5DC?P_X7U/P\NG>0"DXN[FRF,WF;LJ5^R!=NTYWYR,<@'H]?,OC_`/;W
MOO"'[;FE^"(=!BN/AG:W$'AGQ'XI,A`TKQ)?H)].L@.A0Q*J2-_#+?V:\;C7
MTK?O)'8S-$RK*L;%"R[E!QP2,C(SVR*^2K/_`((Y?"OQ%\#=4T?Q-!/X@\=>
M)A<:EJOC5GE@U"XUB=S-_:21K)Y:213;&B7D((8ER0M`'UU7R9^W?^VAK_[/
M/[0?A+PK8^./AM\/]*U;PKJVOO>^+;"6Z34;JUN+.**RB$=Q$^YUN)&P@D<[
M/E4]*^F?AS9ZGIWP_P!$MM:U--:UBWL88K[4$MA;+?3J@#S"(,PCWL"VT,0,
MXR:\?_:;_81\._M4_%_3-?\`$=_=1P:;X7OM$M8K6,1W5A=37EE=0:E;7(.Z
M&YMY+-&0JIY;DX!4@'H_[.?Q'U;XP?`/P9XKU[0+CPKK?B/1;34K[1YR?,TV
M:6)7>%MP#94DCY@#QR`<BO,_^"C/[9-]^Q'\&-#\3Z5X>N/%>H:EXDLM-.E6
MRE[B>S^>XOY(E')>*QM[J4#N8P.<XKUOX1:;KFB?#71['Q+K<?B77K&W%M?:
MLED+(:C(A*F8PJS+&6QDJIQDG&!@#F/BK\`H_BE\?OAEXKN]3>.T^';ZG>Q:
M7]G#QWUS=6OV1)6<M\OE12W``VG)FZC;R`>6?M)_\%'-+^$_QC^!OAKPS;0^
M)K#XHZC:7&JZI`V^WT71;P_9K.\9AP/M%]-;11Y^\/../ER/IZOD/1O^"3OA
MGP3\!/B?X2T?Q-JT-UXRU6UOM(U.YA%Q)X3M;"Y2[TS3K9"PS;6DRN8UR#^]
M;)KZ[0DH,XSCG%`'@?[>_P"U=XF_9P\)Z%I_P\\*IX[^(OB.ZDN+'0O,*&33
MK)1<ZC.2.A$"^5'_`'KBYMU_BKV#X7_$G1OC)\-]!\6>'KQ-0T+Q)80ZE87"
M\"6&5`Z''8X89!Y!R#TKQSQE^P#X,^.O[1'B/X@?$6(>,KAK2VT7P]8S"2VB
M\-V<8\R9(S'(#(]Q._F2.0,B.%<8CR>G_9%_9HM/V2O"6N^#=#U)Y_!T6LSZ
MAX=TMH-@\.6MQB5[%'W$R1+.9G3(!590G(4&@"W^UC^T'-^SI\,K2_TS2%\0
M>)O$>KV?ASP]I;W'V>*^U&[D\N%99<'RX5^:21\$A(VP"<`YWPY\)_'/1_&6
MEWOBGQG\.==T6Z+?VMIECX:NM/DLLHQ4VMPUU*9,/M!$L8W+DY4X%=+^T7\`
M-(_:4^&4WAO5KG4=->.ZM]2TW4].E$5]H]];2K-;7<#D$"2.158;@5895@58
M@\1\(O#/Q>?XD16OB?XH:!K&B^&6Q=PV'@Y=/N];+1L$\Z9KJ5$"L0Q\F)-Q
M4<JN5(![C7Q7\*_VYO$?Q'_:O\6^$M0^)?@OPY%X>\?7'ABS\-?\(;>W=[J-
MK%Y)0F^%P(DDD\QADQX7`R#7VI7S7\+_`($>/O@9\:O%;:)X^\/2>$_&7C*X
M\3WFF7?A5Y+R+[3Y0E@2Z6\50,1_*YA.,\@T`?2E>3?!WXY:OX__`&G_`(Q^
M#+V&Q32O`$NC)ITD2,)I1=V/GR^822#A^!@#`ZYKUFOGKXL?L_>+?`OQOUWQ
M_P##CQSIWAB\^(B6&F:Y8ZOX?_MBU>>W1XH+R#;<0/%(L;;&4LZ.$0[002P!
MUO[%/QPU?]HCX"Q^)]<AL8-0;7=;TPI:(R1>79ZK=V<1PQ)W&.!"W/+$XP.*
MS/\`@H!\0/'OP:_9A\6^.O`6M>'M+OO`^C7VN7%OJ^CR:A%J26]N\BP`I/$8
MB67E_GX/W:Z[]F7X!V/[,GP4TCP;8:A?:NNGM<7-SJ%YM$^H7=S<27-S.P4!
M5,D\TC;5`"A@!P*D_:;^$"?M`_LZ>.O`KZ@^DIXPT&]T9KU(1,UH)X'B\P(2
M`Q7=G&1G'44`2?L_1^+F^&-C<^-==T?Q#K-^JW8N-,TEM,@CB=$98_*::8DJ
M2WS;AG(^48YYK]K+XYZQ\#E^&O\`9$-C-_PE_CS2_#-[]I1FV6UR9?,9,$8D
M&P8)R.O!KTSPOI`\/^&M.L!(918VL5N'(QOV(%SCMG%<+^T=\!T^.P\!A]4D
MTO\`X0[QAI_BA=L`E^UFU\S$!RPVAM_WN<8Z&@#TBOGF?XP?$K]HOXR>-O#?
MPUO_``QX-\+_``[U!-#U/Q%J^F2:M=:EJGV>&YDM[:U6:%4BBCGA#2R.2SLR
MJ@"%C]#5\^?%+]GSQ)\)?B+XF^(?PQ\:6WA67Q=)#<>(]#U71?[6TK4KM(TM
MTO8T6>"6"X,21HY60I((H]R;EW$`]>^$EKXOL?!4,'CF]\/:EX@AED22[T6U
MEM;6YC#'RW\J5W:-RF-R[V`;.#BKGQ&^(.D?";P!K?BC7[V/3M#\/6,VHW]S
M)]V"")"[M[X53P.35#X/>'_$GAOP);P>+/$L7BS7)'DGGOX=,33H2'8LL<<"
ML^U$4A1N=V.,EB37(?M<?LU6G[6G@W1?!FMZE);^#I]8@OO$6F)#N'B.TM\R
MK8.^X&.%YEA:3`)9(RG`<F@#E?V"/VMO$O[2>@^(M.\?^%1X$\>Z!<QWTFAL
MY9QI%\IN-,N#G^,P[H90/NW%K.O85]`U\^^$?^"?O@SX&_M%>&?B#\.HD\&W
M,-I=:+X@LH5DN8O$EE*!)#'(TDA,;P3H)(W&<!YEQB0D?05`'DO[%GQRU?\`
M:&^#-YX@UR&Q@O;?Q/KVC*MHC)&8;'5;JSA)#$G<8X4+'."Q.`!Q7IOB.^NM
M+\/7]S8V9U&]M[>26WM!((S=2*I*Q[CPNX@#)X&:\1_8Z^!'BG]G/5_$7AVY
M\8:3K_A&?5=6UFQM%T!K.^M9K[49;QE>X^TNLJH9W08B0D!3GC!]J\7Z!)XJ
M\)ZGID6HW^D2ZC:2VR7UBZI=63.A42Q%@RAU)W*2",@9!Z4`?-?[`W[4?C+X
M_:])%XM\7>!GUI=*6[USP1'H-WHOB#P=>EDS;LEQ,S7%NN70S^6JLZJR$JV!
M]2U\W?!O]F'Q7KGQ_P##WCCXB>/K'QAJGPNL;W0M&:P\.+I$MTURD2SW-Y()
4Y3*S)&N(T$408E]F=NWZ1H`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
